These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25536639)

  • 41. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
    Suzuki H; Takagi H; Sohara N; Kanda D; Kakizaki S; Sato K; Mori M;
    World J Gastroenterol; 2006 Feb; 12(8):1265-9. PubMed ID: 16534882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 45. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
    Christensen PB; Krarup HB; Laursen AL; Madsen PH; Pedersen C; Schlichting P; Orholm M; Ring-Larsen H; Bukh J; Krogsgaard K
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
    Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
    Lindahl K; Stahle L; Bruchfeld A; Schvarcz R
    Hepatology; 2005 Feb; 41(2):275-9. PubMed ID: 15660393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
    Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford DH; Cheng W; Weltman M; Rawlinson W; Rizkalla B; Depamphilis JK; Roberts SK;
    Hepatology; 2011 Apr; 53(4):1109-17. PubMed ID: 21480317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
    Rubin RA; Russo MW; Brown KA; Fontana RJ; Levitsky J; Vargas H; Yoshida EM; Brown RS
    Exp Clin Transplant; 2018 Apr; 16(2):182-190. PubMed ID: 27855589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
    Herzer K; Papadopoulos-Köhn A; Timm J; Paul A; Jochum C; Gerken G
    Dtsch Med Wochenschr; 2013 Sep; 138(36):1759-64. PubMed ID: 24002874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
    Brogan AJ; Talbird SE; Thompson JR; Miller JD; Rubin J; Deniz B
    PLoS One; 2014; 9(3):e90295. PubMed ID: 24603445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.
    Urquijo JJ; Diago M; Boadas J; Planas R; Solá R; Del Olmo JA; Crespo J; Erdozaín JC; Antón MD; Arocena C; Suarez D; Giné J; Barrera JM; Gracia-Samaniego J; Perez R; Dalmau B; Montoro M
    Ann Hepatol; 2013; 12(1):30-5. PubMed ID: 23293191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.